← All trials
NCT04518748
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 16, 2020
- Primary completion
- Nov 30, 2022
- Completion date
- Sep 30, 2024
- First posted
- Aug 19, 2020
- Last posted
- Oct 27, 2020
- Enrollment
- 45
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of MichiganLead sponsor
- University of MichiganOverall official - principal investigator
- Department of Health and Human ServicesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.